143 related articles for article (PubMed ID: 30106131)
1. Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches.
Yang X; Deng Y; He RQ; Li XJ; Ma J; Chen G; Hu XH
Int J Mol Med; 2018 Nov; 42(5):2650-2664. PubMed ID: 30106131
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
3. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
4. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.
Zhang R; Zhang TT; Zhai GQ; Guo XY; Qin Y; Gan TQ; Zhang Y; Chen G; Mo WJ; Feng ZB
World J Surg Oncol; 2018 Jun; 16(1):109. PubMed ID: 29914539
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
Zhang JT; Lin YC; Xiao BF; Yu BT
Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
[TBL] [Abstract][Full Text] [Related]
6. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway.
Hou XM; Zhang T; Da Z; Wu XA
Pathol Res Pract; 2019 May; 215(5):988-994. PubMed ID: 30826152
[TBL] [Abstract][Full Text] [Related]
7. Function of low ADARB1 expression in lung adenocarcinoma.
Wang X; Xu Z; Ren X; Chen X; Wei J; Lin W; Li Z; Ou C; Gong Z; Yan Y
PLoS One; 2019; 14(9):e0222298. PubMed ID: 31491024
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic role of miR‑183‑5p in lung adenocarcinoma: A comprehensive study of qPCR, in vitro experiments and bioinformatic analysis.
He RQ; Gao L; Ma J; Li ZY; Hu XH; Chen G
Oncol Rep; 2018 Jul; 40(1):83-100. PubMed ID: 29749535
[TBL] [Abstract][Full Text] [Related]
9. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.
Bai Y; Xiong L; Zhu M; Yang Z; Zhao J; Tang H
Cancer Biomark; 2019; 24(3):371-382. PubMed ID: 30883337
[TBL] [Abstract][Full Text] [Related]
10. Identification of LBX2 as a novel causal gene of lung adenocarcinoma.
Hu J; Bai Y; Zhang Q; Li M; Yin R; Xu L
Thorac Cancer; 2020 Aug; 11(8):2137-2145. PubMed ID: 32567804
[TBL] [Abstract][Full Text] [Related]
11. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
12. CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
Luo J; Chimge NO; Zhou B; Flodby P; Castaldi A; Firth AL; Liu Y; Wang H; Yang C; Marconett CN; Crandall ED; Offringa IA; Frenkel B; Borok Z
Int J Cancer; 2018 Dec; 143(12):3169-3180. PubMed ID: 30325015
[TBL] [Abstract][Full Text] [Related]
13. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis.
Gan TQ; Chen WJ; Qin H; Huang SN; Yang LH; Fang YY; Pan LJ; Li ZY; Chen G
Med Sci Monit; 2017 May; 23():2453-2464. PubMed ID: 28533502
[TBL] [Abstract][Full Text] [Related]
15. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
Liu C; Li Z; Wang S; Fan Y; Zhang S; Yang X; Hou K; Tong J; Hu X; Shi X; Wang X; Liu Y; Che X; Qu X
J Cancer Res Clin Oncol; 2019 Jan; 145(1):65-76. PubMed ID: 30357521
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism.
Yang DP; Huang WY; Chen G; Chen SW; Yang J; He RQ; Huang SN; Gan TQ; Ma J; Yang LJ; Song JH; Mo JX; Tang ZQ; Li CB; Zhou HF; Kong JL
Comput Biol Chem; 2020 Dec; 89():107383. PubMed ID: 33032037
[TBL] [Abstract][Full Text] [Related]
17. Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.
Tsoyi K; Osorio JC; Chu SG; Fernandez IE; De Frias SP; Sholl L; Cui Y; Tellez CS; Siegfried JM; Belinsky SA; Perrella MA; El-Chemaly S; Rosas IO
Am J Respir Cell Mol Biol; 2019 Jun; 60(6):659-666. PubMed ID: 30562054
[TBL] [Abstract][Full Text] [Related]
18. Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
Zhao M; Chen Z; Zheng Y; Liang J; Hu Z; Bian Y; Jiang T; Li M; Zhan C; Feng M; Wang Q
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1463-1472. PubMed ID: 32221746
[TBL] [Abstract][Full Text] [Related]
19. Expression levels and co‑targets of miRNA‑126‑3p and miRNA‑126‑5p in lung adenocarcinoma tissues: Αn exploration with RT‑qPCR, microarray and bioinformatic analyses.
Chen P; Gu YY; Ma FC; He RQ; Li ZY; Zhai GQ; Lin X; Hu XH; Pan LJ; Chen G
Oncol Rep; 2019 Feb; 41(2):939-953. PubMed ID: 30535503
[TBL] [Abstract][Full Text] [Related]
20. Identification of CAV1 and DCN as potential predictive biomarkers for lung adenocarcinoma.
Yan Y; Xu Z; Qian L; Zeng S; Zhou Y; Chen X; Wei J; Gong Z
Am J Physiol Lung Cell Mol Physiol; 2019 Apr; 316(4):L630-L643. PubMed ID: 30604627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
